O	0	6	Impact
O	7	9	of
B-intervention	10	18	exercise
I-intervention	19	27	training
O	28	30	on
B-condition	31	45	cardiotoxicity
O	46	49	and
O	50	57	cardiac
O	58	64	health
O	65	73	outcomes
O	74	76	in
O	77	82	women
O	83	87	with
O	88	94	breast
O	95	101	cancer
O	102	115	anthracycline
O	116	128	chemotherapy
O	128	129	:
O	130	131	a
O	132	137	study
O	138	146	protocol
O	147	150	for
O	151	152	a
O	153	163	randomized
O	164	174	controlled
O	175	180	trial
O	180	181	.

O	182	196	Anthracyclines
O	197	200	are
O	201	217	chemotherapeutic
O	218	224	agents
O	225	235	frequently
O	236	240	used
O	241	243	in
O	244	250	breast
O	251	257	cancer
O	258	259	(
O	259	261	BC
O	261	262	)
O	263	272	treatment
O	272	273	.

O	274	282	Although
O	283	285	it
O	286	294	improves
O	295	302	disease
O	302	303	-
O	303	307	free
O	308	311	and
O	312	319	overall
O	320	328	survival
O	328	329	,
O	330	333	the
O	334	337	use
O	338	340	of
O	341	355	anthracyclines
O	356	358	is
O	359	369	associated
O	370	374	with
O	375	376	a
O	377	387	cumulative
O	388	392	risk
O	393	395	of
O	396	403	cardiac
O	404	412	toxicity
O	412	413	.

O	414	424	Preventive
O	425	435	strategies
O	436	438	to
O	439	447	optimize
O	448	455	cardiac
O	456	462	health
O	463	466	are
O	467	473	needed
O	474	477	and
O	478	486	exercise
O	487	489	is
O	490	498	proposed
O	499	501	as
O	502	503	a
O	504	513	potential
O	514	517	non
O	517	518	-
O	518	533	pharmacological
O	534	542	approach
O	543	546	for
O	547	560	counteracting
O	561	574	anthracycline
O	574	575	-
O	575	582	related
O	583	597	cardiotoxicity
O	598	599	(
O	599	602	ARC
O	602	603	)
O	603	604	.

O	605	609	Most
O	610	612	of
O	613	616	the
O	617	621	data
O	622	624	on
O	625	628	the
O	629	636	effects
O	637	639	of
O	640	648	exercise
O	649	651	to
O	652	658	reduce
O	659	662	ACT
O	663	666	are
O	667	671	from
O	672	678	animal
O	679	686	studies
O	686	687	,
O	688	692	with
O	693	697	only
O	698	699	a
O	700	703	few
O	704	711	studies
O	712	714	in
O	715	716	a
O	717	724	limited
O	725	731	number
O	732	734	of
O	735	743	patients
O	744	754	indicating
O	755	765	beneficial
O	766	773	effects
O	773	774	.

O	775	777	To
O	778	784	better
O	785	795	understand
O	796	799	the
O	800	813	effectiveness
O	814	816	of
O	817	825	exercise
O	826	828	in
O	829	832	the
O	833	843	mitigation
O	844	846	of
O	847	850	ARC
O	850	851	,
O	852	860	clinical
O	860	861	,
O	862	866	real
O	866	867	-
O	867	872	world
O	873	879	trials
O	880	885	claim
O	886	893	require
O	894	895	a
O	896	902	larger
O	903	909	sample
O	910	914	size
O	915	918	and
O	919	923	more
O	924	932	accurate
O	933	936	and
O	937	945	valuable
O	946	954	clinical
O	955	965	biomarkers
O	965	966	.

O	967	969	In
O	970	974	this
O	975	980	study
O	980	981	,
O	982	984	we
O	985	991	intend
O	992	994	to
O	995	1002	include
O	1003	1004	a
O	1005	1010	large
O	1011	1017	sample
O	1018	1021	and
O	1022	1033	investigate
O	1034	1041	cardiac
O	1042	1050	function
O	1051	1058	through
O	1059	1065	serial
O	1066	1074	measures
O	1075	1077	of
O	1078	1088	biomarkers
O	1089	1092	and
O	1093	1100	imaging
O	1101	1111	techniques
O	1111	1112	.

O	1113	1117	This
O	1118	1126	protocol
O	1127	1136	describes
O	1137	1138	a
O	1139	1142	two
O	1142	1143	-
O	1143	1146	arm
O	1146	1147	,
O	1148	1159	prospective
O	1159	1160	,
O	1161	1171	randomized
O	1172	1182	controlled
O	1183	1188	trial
O	1189	1193	that
O	1194	1198	will
O	1199	1206	explore
O	1207	1210	the
O	1211	1227	cardioprotective
O	1228	1234	effect
O	1235	1237	of
O	1238	1239	a
O	1240	1250	structured
O	1251	1259	exercise
O	1260	1267	program
O	1268	1270	in
B-eligibility	1271	1276	women
I-eligibility	1277	1281	with
I-eligibility	1282	1284	BC
I-eligibility	1285	1295	undergoing
I-eligibility	1296	1309	anthracycline
I-eligibility	1309	1310	-
I-eligibility	1310	1320	containing
I-eligibility	1321	1333	chemotherapy
I-eligibility	1334	1335	(
I-eligibility	1335	1338	ACT
I-eligibility	1338	1339	)
O	1339	1340	.

B-total-participants	1341	1347	Ninety
O	1348	1353	adult
O	1354	1359	women
O	1360	1364	with
O	1365	1370	early
O	1371	1373	BC
O	1374	1377	and
O	1378	1389	recommended
O	1390	1392	to
O	1393	1400	receive
O	1401	1404	ACT
O	1405	1409	will
O	1410	1412	be
O	1413	1421	randomly
O	1422	1430	assigned
O	1431	1432	(
O	1432	1433	1
O	1433	1434	:
O	1434	1435	1
O	1435	1436	)
O	1437	1439	to
O	1440	1442	an
O	1443	1455	intervention
O	1456	1461	group
O	1462	1464	or
O	1465	1466	a
B-control	1467	1474	control
I-control	1475	1480	group
O	1480	1481	.

O	1482	1490	Patients
O	1491	1500	allocated
O	1501	1503	to
O	1504	1507	the
O	1508	1520	intervention
O	1521	1526	group
O	1527	1531	will
O	1532	1539	perform
O	1540	1541	a
O	1542	1552	supervised
O	1553	1561	exercise
O	1562	1569	program
O	1570	1575	three
O	1576	1581	times
O	1582	1585	per
O	1586	1590	week
O	1590	1591	,
O	1592	1602	consisting
O	1603	1605	of
O	1606	1607	a
O	1608	1619	combination
O	1620	1622	of
O	1623	1630	aerobic
O	1631	1634	and
O	1635	1645	resistance
O	1646	1654	training
O	1655	1659	with
O	1660	1671	progressive
O	1672	1681	intensity
O	1682	1685	and
O	1686	1692	volume
O	1692	1693	,
O	1694	1700	during
O	1701	1704	the
O	1705	1709	time
O	1710	1716	period
O	1717	1721	they
O	1722	1729	receive
O	1730	1733	ACT
O	1733	1734	.

O	1735	1738	The
O	1739	1746	control
O	1747	1752	group
O	1753	1757	will
O	1758	1765	receive
O	1766	1774	standard
O	1775	1777	BC
O	1778	1782	care
O	1782	1783	.

O	1784	1791	Primary
O	1792	1800	outcomes
O	1801	1808	related
O	1809	1811	to
O	1812	1819	cardiac
O	1820	1821	(
O	1821	1824	dys
O	1824	1825	)
O	1825	1833	function
O	1834	1838	will
O	1839	1841	be
B-outcome-Measure	1842	1853	circulating
I-outcome-Measure	1854	1855	N
I-outcome-Measure	1855	1856	-
I-outcome-Measure	1856	1864	terminal
I-outcome-Measure	1865	1868	pro
I-outcome-Measure	1868	1869	-
I-outcome-Measure	1869	1874	brain
I-outcome-Measure	1875	1886	natriuretic
I-outcome-Measure	1887	1894	peptide
I-outcome-Measure	1895	1896	(
I-outcome-Measure	1896	1898	NT
I-outcome-Measure	1898	1899	-
I-outcome-Measure	1899	1905	proBNP
I-outcome-Measure	1905	1906	)
I-outcome-Measure	1907	1913	levels
O	1913	1914	,
B-outcome-Measure	1915	1922	resting
I-outcome-Measure	1923	1927	left
I-outcome-Measure	1928	1939	ventricular
I-outcome-Measure	1940	1941	(
I-outcome-Measure	1941	1943	LV
I-outcome-Measure	1943	1944	)
I-outcome-Measure	1945	1957	longitudinal
I-outcome-Measure	1958	1964	strain
O	1964	1965	,
O	1966	1969	and
B-outcome-Measure	1970	1977	resting
I-outcome-Measure	1978	1980	LV
I-outcome-Measure	1981	1989	ejection
I-outcome-Measure	1990	1998	fraction
O	1998	1999	.

O	2000	2009	Secondary
O	2010	2018	outcomes
O	2019	2023	will
O	2024	2031	include
O	2032	2035	the
O	2036	2046	assessment
O	2047	2049	of
B-outcome-Measure	2050	2057	resting
I-outcome-Measure	2058	2063	blood
I-outcome-Measure	2064	2072	pressure
O	2072	2073	,
B-outcome-Measure	2074	2081	resting
I-outcome-Measure	2082	2087	heart
I-outcome-Measure	2088	2092	rate
I-outcome-Measure	2093	2094	(
I-outcome-Measure	2094	2096	HR
I-outcome-Measure	2096	2097	)
O	2097	2098	,
B-outcome-Measure	2099	2106	resting
I-outcome-Measure	2107	2109	HR
I-outcome-Measure	2110	2121	variability
I-outcome-Measure	2122	2123	(
I-outcome-Measure	2123	2126	HRV
I-outcome-Measure	2126	2127	)
O	2127	2128	,
B-outcome-Measure	2129	2137	recovery
I-outcome-Measure	2138	2140	HR
O	2140	2141	,
B-outcome-Measure	2142	2150	physical
I-outcome-Measure	2151	2159	function
I-outcome-Measure	2160	2168	outcomes
O	2168	2169	,
B-outcome-Measure	2170	2174	self
I-outcome-Measure	2174	2175	-
I-outcome-Measure	2175	2183	reported
I-outcome-Measure	2184	2192	physical
I-outcome-Measure	2193	2201	activity
I-outcome-Measure	2202	2207	level
O	2207	2208	,
B-outcome-Measure	2209	2215	health
I-outcome-Measure	2215	2216	-
I-outcome-Measure	2216	2223	related
I-outcome-Measure	2224	2231	quality
I-outcome-Measure	2232	2234	of
I-outcome-Measure	2235	2239	life
O	2239	2240	,
O	2241	2244	and
B-outcome-Measure	2245	2252	fatigue
O	2252	2253	.

O	2254	2258	Data
O	2259	2263	will
O	2264	2266	be
O	2267	2275	obtained
O	2276	2278	at
O	2279	2287	baseline
O	2288	2289	(
O	2289	2291	t0
O	2291	2292	)
O	2292	2293	,
O	2294	2299	after
O	2300	2303	the
O	2304	2307	end
O	2308	2310	of
O	2311	2324	anthracycline
O	2324	2325	-
O	2325	2334	treatment
O	2335	2336	(
O	2336	2338	t2
O	2338	2339	)
O	2339	2340	,
O	2341	2344	and
O	2345	2346	3
O	2347	2353	months
O	2354	2359	after
O	2360	2362	t2
O	2363	2364	(
O	2364	2366	t3
O	2366	2367	)
O	2367	2368	.

O	2369	2381	Additionally
O	2381	2382	,
O	2383	2385	NT
O	2385	2386	-
O	2386	2392	proBNP
O	2393	2397	will
O	2398	2400	be
O	2401	2409	measured
O	2410	2411	1
O	2411	2412	-
O	2412	2414	24
O	2415	2416	h
O	2417	2422	prior
O	2423	2425	to
O	2426	2430	each
O	2431	2444	anthracycline
O	2444	2445	-
O	2445	2454	treatment
O	2455	2460	cycle
O	2461	2462	(
O	2462	2464	t1
O	2464	2465	)
O	2465	2466	.

O	2467	2470	The
O	2471	2485	implementation
O	2486	2488	of
O	2489	2492	the
O	2493	2500	present
O	2501	2506	study
O	2507	2513	design
O	2513	2514	,
O	2515	2520	using
O	2521	2526	novel
O	2527	2535	clinical
O	2536	2546	biomarkers
O	2546	2547	,
O	2548	2552	will
O	2553	2562	determine
O	2563	2566	the
O	2567	2573	effect
O	2574	2576	of
O	2577	2587	structured
O	2588	2596	exercise
O	2597	2610	interventions
O	2611	2613	at
O	2614	2624	mitigating
O	2625	2628	ARC
O	2628	2629	,
O	2630	2634	with
O	2635	2638	the
O	2639	2646	overall
O	2647	2650	aim
O	2651	2653	of
O	2654	2661	finding
O	2662	2667	means
O	2668	2670	to
O	2671	2678	further
O	2679	2686	improve
O	2687	2689	BC
O	2690	2694	care
O	2694	2695	.

O	2696	2702	ISRCTN
O	2702	2703	,
O	2704	2718	ISRCTN32617901
O	2719	2720	.

O	2721	2731	Registered
O	2732	2734	on
O	2735	2737	24
O	2738	2745	October
O	2746	2750	2018
O	2750	2751	.

O	2752	2756	Last
O	2757	2764	updated
O	2765	2767	on
O	2768	2770	11
O	2771	2778	January
O	2779	2783	2019
O	2783	2784	.
